Citius Oncology/$CTOR
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Citius Oncology
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
Ticker
$CTOR
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
-
ISIN
US17331Y1091
Citius Oncology Metrics
BasicAdvanced
$379M
-
-$0.37
-0.06
-
Price and volume
Market cap
$379M
Beta
-0.06
52-week high
$6.19
52-week low
$0.55
Average daily volume
2.2M
Financial strength
Current ratio
0.363
Long term debt to equity
10.662
Total debt to equity
10.662
Profitability
Effective tax rate (TTM)
-3.24%
Management effectiveness
Return on assets (TTM)
-22.41%
Return on equity (TTM)
-93.64%
Valuation
Price to book
10.62
Price to tangible book (TTM)
10.62
Price to free cash flow (TTM)
-76.067
Free cash flow yield (TTM)
-1.31%
Free cash flow per share (TTM)
-6.95%
Growth
Earnings per share change (TTM)
43.17%
Bulls say / Bears say
FDA approval of LYMPHIR for cutaneous T-cell lymphoma positions Citius Oncology to enter a market exceeding $400 million, potentially driving significant revenue growth. (seekingalpha.com)
The distribution agreement with Cardinal Health enhances LYMPHIR's market reach, ensuring efficient delivery to healthcare providers and patients. (gurufocus.com)
Ongoing Phase I trials combining LYMPHIR with pembrolizumab show promising preliminary results, indicating potential for expanded indications and increased market share. (marketscreener.com)
A net loss of $7.7 million in Q2 2025, up from $4.8 million the previous year, reflects escalating operating expenses and financial strain. (seekingalpha.com)
With only $112 in cash reserves as of March 31, 2025, Citius Oncology faces an urgent need for additional capital to sustain operations beyond May 2025. (seekingalpha.com)
The necessity to secure additional funding may lead to shareholder dilution, potentially impacting stock value and investor confidence. (seekingalpha.com)
Data summarised monthly by Lightyear AI. Last updated on 28 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Citius Oncology stock?
Citius Oncology (CTOR) has a market cap of $379M as of July 05, 2025.
What is the P/E ratio for Citius Oncology stock?
The price to earnings (P/E) ratio for Citius Oncology (CTOR) stock is 0 as of July 05, 2025.
Does Citius Oncology stock pay dividends?
No, Citius Oncology (CTOR) stock does not pay dividends to its shareholders as of July 05, 2025.
When is the next Citius Oncology dividend payment date?
Citius Oncology (CTOR) stock does not pay dividends to its shareholders.
What is the beta indicator for Citius Oncology?
Citius Oncology (CTOR) has a beta rating of -0.06. This means that it has an inverse relation to market volatility.